Barclays analyst Carter Gould maintains $AbbVie (ABBV.US)$ with a buy rating, and maintains the target price at $212.
According to TipRanks data, the analyst has a success rate of 48.6% and a total average return of 8.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:
AbbVie has recorded another remarkable quarter, shifting the attention towards emraclidine and the year 2025.
Following AbbVie's report of robust Q3 results and an increase in revenue guidance for 2024, there's an acknowledgment of the company's strong prospects heading towards the year-end. This positive sentiment is supported by a more optimistic 2025 earnings per share forecast. Nevertheless, the assessment of the company's long-term growth potential is measured against its present market valuation.
Following AbbVie's third-quarter report, which surpassed expectations and projected higher future earnings, confidence in the company's growth outlook has been bolstered. The revision of estimates is primarily due to increased projections for Rinvoq and Skyrizi, although this is somewhat balanced by tempered forecasts for aesthetics and Humira sales.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克萊銀行分析師Carter Gould維持$艾伯維公司 (ABBV.US)$買入評級，維持目標價212美元。
根據TipRanks數據顯示，該分析師近一年總勝率為48.6%，總平均回報率為8.9%。
此外，綜合報道，$艾伯維公司 (ABBV.US)$近期主要分析師觀點如下：
艾伯維公司已經記錄下另一個顯著季度的成績，將注意力轉向emraclidine和2025年。
在艾伯維公司發佈強勁的第三季度業績報告，並提高了2024年營業收入指引後，人們開始認可該公司朝着年底的強勁前景。這種積極情緒得到更樂觀的2025年每股收益預測的支持。然而，對公司長期增長潛力的評估是根據其目前市場估值而平衡的。
在艾伯維公司第三季度報告之後，超出預期並預測未來收益增長，使人們對公司的增長前景信心增強。對估值的修訂主要是由於對Rinvoq和Skyrizi的預期增加，儘管在美學和Humira銷售預測方面略有平衡。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
